Canada Specialty Pharmacy Market
Market Size in USD Billion
CAGR : %
Forecast Period |
2024 –2030 |
Market Size (Base Year) |
|
Market Size (Forecast Year) |
USD 14,192.50 |
CAGR |
|
Major Markets Players |
Canada Specialty Pharmacy Market, By Service Type (Clinical Services, Operational Services, and Other Services), Type (Large Pharmacy Benefit Manager and Small- Independent Pharmacy Service Providers), Condition (Anemia, Cancer, HIV, Infertility, Multiple Sclerosis, Rheumatoid Arthritis, Growth Hormone Deficiencies, Hepatitis C Virus, Hemophilia, Psoriasis, Pulmonary Hypertension, Crohn's Disease, Cystic Fibrosis, Immune Deficiency, Osteoarthritis, Juvenile Idiopathic Arthritis, Ulcerative Colitis, and Others) - Industry Trends and Forecast to 2030.
Canada Specialty Pharmacy Market Analysis and Size
The model of a specialty pharmacy is intended to provide a comprehensive and coordinated model of care for patients with chronic illnesses and complex medical conditions, achieve superior clinical and economic outcomes, and expedite patient access to care. Specialty pharmacies connect severely ill patients with the medications prescribed for their conditions, provide the patient care services required for these medications, and support patients who are facing reimbursement challenges for these life-changing and at times, life-saving but frequently expensive medications.
The increasing geriatric population is expected to drive the segment's growth. However, the stringent regulatory framework is expected to hinder the Canada specialty pharmacy market's growth.
Data Bridge Market Research analyses that the Canada specialty pharmacy market is expected to reach the value of USD 14,192.50 million by 2030, at a CAGR of 11.3% during the forecast period. Clinical services account for the largest segment in the Canada specialty pharmacy market.
Report Metric |
Details |
Forecast Period |
2023 to 2030 |
Base Year |
2022 |
Historic Year |
2021 (Customizable to 2020-2015) |
Quantitative Units |
Revenue in USD Million |
Segments Covered |
By Service Type (Clinical Services, Operational Services, and Other Services), Type (Large Pharmacy Benefit Manager and Small- Independent Pharmacy Service Providers), Condition (Anemia, Cancer, HIV, Infertility, Multiple Sclerosis, Rheumatoid Arthritis, Growth Hormone Deficiencies, Hepatitis C Virus, Hemophilia, Psoriasis, Pulmonary Hypertension, Crohn's Disease, Cystic Fibrosis, Immune Deficiency, Osteoarthritis, Juvenile Idiopathic Arthritis, Ulcerative Colitis, and Others) |
Country Covered |
Canada |
Market Players Covered |
McKesson Canada, Bayshore HealthCare, SRx Health, Sentrex Health Solutions, Sobeys Inc., PHARMASAVE, Lovell Drugs, Create Compounding Ltd., Dynasty Pharmacy, Resident Care Pharmacy, Pace Pharmacy, Northmount Pharmacy and Compounding Lab, Medicine Centre, riverviewguardian.ca, Brunskillpharmacy, Extend Pharmacy, Sherman Specialty Pharmacy, Quiick Medicine, Allcures Pharmacy, Alpine Drug Mart I.D.A., PharmaChoiceAnchor Compounding Pharmacy, Andreen's Pharmacy, Balanced Health Integrative Pharmacy, Bains Pharmacy, Shoppers Drug Mart Specialty Health Network Inc., MEDS among others |
Market Definition
Specialty pharmacies differ from traditional pharmacies in that they coordinate many aspects of patient care and disease management. They are intended to deliver medications with special handling, storage, and distribution requirements in a standardized manner that allows for economies of scale. Specialty pharmacies are also intended to improve clinical and economic outcomes for patients suffering from complex, often chronic, and rare conditions, with close contact and management by clinicians. Specialty pharmacies employ healthcare professionals who educate patients, help ensure appropriate medication use, promote adherence, and try to avoid unnecessary costs. Other support systems coordinate information sharing among clinicians treating patients and assist patients in locating resources to help with out-of-pocket expenses.
Canada Specialty Pharmacy Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:
Drivers/Opportunities
- Increasing prevalence of chronic and rare diseases
With the rising economic growth, people are more interested in long-term health and wellness. Patients with chronic diseases need to monitor their health on a regular basis. Specialty pharmacy services help manage chronic and rare diseases due to the availability of specialty drugs for chronic diseases such as diabetes, heart failure or chronic obstructive pulmonary disease (COPD), cancer, and rare diseases such as autoimmune disorders, namely eosinophilic granulomatosis with polyangiitis (EGPA), Guillain-Barre syndrome, Kawasaki disease among others. Its service includes medication dispensing and providing other healthcare assistance.
- Increasing geriatric population
As the geriatric population is more prone to chronic disease and injuries, the prevalence rate of their diseases and injuries in Canada leads to demand for specialty pharmacy services to monitor and care for their health. Therefore, the geriatric population and its rising disease rates play a major role in driving the specialty pharmacy market. These services use a unique combination of digital tools and compassionate clinical services to deliver fertility medication, nurse-administered home infusions, and care for people living with everything from rheumatoid arthritis, cancer, and HIV to the rarest of rare conditions.
- Emerging markets of specialty pharmacies
A major factor in the growth of the specialized pharmacy market is the aging population. Diabetes due to an unhealthy lifestyle and rising dementia, Alzheimer's, and Parkinson's diseases are common in the geriatric population. From 2015 to 2021, the number of seniors is projected to exceed the number of children aged 14 and younger for the first time. By 2036, seniors could reach between 9.9 and 10.9 million people. According to a medium-growth scenario, the number of people aged 80 and older is expected to double to 3.3 million by 2036. The population aged 100 and older could triple to more than 20,000. Apart from the geriatric population, GDP, population density, and improving access to the specialized pharmacy market create growth opportunities.
Restraints/Challenges
- Stringent regulatory framework
Canada's federal and provincial governments jointly set their pharmaceutical policy. The federal government is in charge of protecting producers' intellectual property rights (patents), initial approval, labelling, and overall market competition for prescription medications. The provincial government is in charge of and has authority over financing all medical services, including prescription drugs. Moreover, specialty drugs come under high-risk drugs, including those for chronic diseases such as cancer and rare diseases such as autoimmune diseases. Therefore, there are different sets of regulatory frameworks for the distribution as well as manufacturing of these drugs.
- Insufficient funding for specialty pharmacies
The mortality ratio due to chronic diseases is very high in the Canadian region. One of the major reasons for this is the insufficient funding for specialty pharmacies which leads to a decrease in the number of specialty pharmacies.
Specialty pharmacies deal with specialty drugs for chronic diseases and rare diseases. A specialty pharmacy is a state-licensed pharmacy that solely or largely provides medications for people with serious health conditions requiring complex therapies. These medications and therapies have very out-of-pocket rates, which in turn makes the specialty pharmacy a very costly business to start with, which requires huge amounts of investments and funding. The negligent government aid and initiatives are leading to the decline of these pharmacies.
Thus, the insufficient funding for specialty pharmacies may act as a challenge in the growth of Canada specialty pharmacy market.
Post COVID-19 Impact on Canada Specialty Pharmacy Market
The coronavirus pandemic has affected Canada's specialty pharmacy industry across four main areas: product sourcing and procurement, product launch and distribution, acquisition and access, and treatment and care management. Specialty pharmacies have risen to the occasion by working closely with federal and provincial government agencies to address challenges experienced by the healthcare system to combat the COVID-19 pandemic. These include exploring new ways of working, increasing testing capacity and results tracking for COVID-19, and ultimately working toward the development, manufacture, and delivery of safe and effective vaccines and treatment. Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple strategies and programs for the specialty pharmacy market.
Recent Development
- In March 2022, BioScript solutions and NeonMind announced the strategic partnership to expand the specialty clinic network for interventional psychiatry treatments. This partnership will leverage the BioScript solutions in an extensive national network of community-based infusion clinics to expand access to NeonMind's interventional psychiatry and unique treatment programs for Canadians
Canada Specialty Pharmacy Market Scope
Canada specialty pharmacy market is categorized into three segments, which are based on service type, type, and condition. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Service Type
- Clinical services
- Operational services
- Other services
On the basis of service type, the Canada specialty pharmacy market is segmented into clinical services, operational services, and other services.
- Type
- Large pharmacy benefit manager (PBM)
- Small-independent pharmacy service providers
On the basis of type, the Canada specialty pharmacy market has been segmented into large pharmacy benefit manager (PBM) and small-independent pharmacy service providers.
- Condition
- Anemia
- Cancer
- HIV
- Infertility
- Multiple sclerosis
- Rheumatoid arthritis
- Growth hormone deficiencies
- Hepatitis c virus
- Hemophilia
- Psoriasis
- Pulmonary hypertension
- Crohn's disease
- Cystic fibrosis
- Immune deficiency
- Osteoarthritis
- Juvenile idiopathic arthritis
- Ulcerative colitis
- Others
On the basis of condition, the Canada specialty pharmacy market has been segmented into anemia, cancer, HIV, infertility, multiple sclerosis, rheumatoid arthritis, growth hormone deficiencies, hepatitis C virus, hemophilia, psoriasis, pulmonary hypertension, Crohn's disease, cystic fibrosis, immune deficiency, osteoarthritis, juvenile idiopathic arthritis, ulcerative colitis, and others.
Canada Specialty Pharmacy Market Regional Analysis/Insights
Canada specialty pharmacy market is analyzed, and market size insights and trends are provided by country, service type, type, and conditions as referenced above.
Canada specialty pharmacy market is growing because of the increasing demand for specialty drugs, increasing distribution channels as well as growing prevalence of chronic conditions are expected to drive the market's growth.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends and porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Canada Specialty Pharmacy Market Share Analysis
Canada specialty pharmacy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies focus on the specialty pharmacy market.
Some of the major players operating in the specialty pharmacy market are McKesson Canada, Bayshore HealthCare, SRx Health, Sentrex Health Solutions, Sobeys Inc., PHARMASAVE, Lovell Drugs, Create Compounding Ltd., Dynasty Pharmacy, Resident Care Pharmacy, Pace Pharmacy, Northmount Pharmacy and Compounding Lab, Medicine Centre, riverviewguardian.ca, Brunskillpharmacy, Extend Pharmacy, Sherman Specialty Pharmacy, Quiick Medicine, Allcures Pharmacy, Alpine Drug Mart I.D.A., PharmaChoiceAnchor Compounding Pharmacy, Andreen's Pharmacy, Balanced Health Integrative Pharmacy, Bains Pharmacy, Shoppers Drug Mart Specialty Health Network Inc., MEDS among others.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE CANADA SPECIALTY PHARMACY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 SERVICE TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 CANADA SPECIALTY PHARMACY MARKET, DISTRIBUTION MODEL
4.4 CANADA SPECIALTY PHARMACY MARKET, KEY STRATEGIC INITIATIVES
4.5 CANADA SPECIALTY PHARMACY MARKET, PATIENT ASSISTANCE PROGRAMS IN CANADA
4.6 CANADA SPECIALTY PHARMACY MARKET, INDUSTRY INSIGHTS
4.7 CANADA SPECIALTY PHARMACY MARKET, REGULATIONS
5 LIST OF SMALL ENTERPRISES
6 EPIDEMEOLOGY
7 COUNTRY WRITE-UP
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASING PREVALENCE OF CHRONIC AND RARE DISEASES
8.1.2 INCREASING GERIATRIC POPULATION
8.1.3 INSURANCE COVERAGE
8.1.4 INCREASING NUMBER OF DISTRIBUTION CHANNELS FOR SPECIALITY DRUGS
8.2 RESTRAINTS
8.2.1 STRINGENT REGULATORY FRAMEWORK
8.2.2 LACK OF SKILLED PHARMACISTS
8.3 OPPORTUNITIES
8.3.1 EMERGING MARKETS OF SPECIALTY PHARMACIES
8.3.2 RISING E-PHARMACIES FACILITIES
8.4 CHALLENGES
8.4.1 LACK OF AWARENESS AMONG CONSUMERS ABOUT SPECIALTY PHARMACIES
8.4.2 INSUFFICIENT FUNDING FOR SPECIALITY PHARMACIES
9 CANADA SPECIALTY PHARMACY MARKET, BY SERVICE TYPE
9.1 OVERVIEW
9.2 CLINICAL SERVICES
9.2.1 COMPOUNDING
9.2.2 AUTO-REFILLS/REFILLS
9.2.3 BLISTER PACKAGING
9.2.4 MEDICAL CONSULTATIONS
9.2.4.1 PATIENT SIDE EFFECTS
9.2.4.2 ADVERSE DRUG REACTIONS
9.2.4.3 NON-COMPLIANCE
9.2.4.4 OTHER PATIENT CONCERNS
9.2.5 CARE MANAGEMENT
9.2.6 PATIENT ADHERENCE PROGRAMS
9.2.7 HEALTH CARE PROVIDER ACCESS
9.2.8 CLINICAL OUTCOME MEASURES
9.2.9 RISK EVALUATION AND MITIGATION STRATEGIES (REMS) PROGRAMS
9.2.9.1 REMS REPORTING
9.2.9.2 PHASE IV TRIALS
9.2.9.3 CLINICAL AND COGNITIVE COUNSELING
9.3 OPERATIONAL SERVICES
9.3.1 SUPPLY CHAIN MANAGEMENT
9.3.1.1 STORAGE & HANDLING
9.3.1.2 DISTRIBUTION
9.3.2 CARE COORDINATION
9.3.3 INSURANCE NAVIGATION
9.3.3.1 UTILIZATION MANAGEMENT
9.3.3.2 PRIOR AUTHORIZATION PROCESSES
9.3.4 PATIENT ASSISTANCE
9.3.5 PLAN OPTIMIZATION
9.4 OTHER SERVICES
10 CANADA SPECIALTY PHARMACY MARKET, BY TYPE
10.1 OVERVIEW
10.2 LARGE PHARMACY BENEFIT MANAGER (PBM)
10.2.1 MANUFACTURER-OWNED SPECIALTY PHARMACIES
10.2.2 OWNED SPECIALTY PHARMACIES
10.3 SMALL INDEPENDENT PHARMACY SERVICE PROVIDERS
11 CANADA SPECIALTY PHARMACY MARKET, BY CONDITION
11.1 OVERVIEW
11.2 CANCER
11.3 RHEUMATOID ARTHRITIS
11.4 MULTIPLE SCLEROSIS
11.5 OSTEOARTHRITIS
11.6 INFERTILITY
11.7 HIV
11.8 PULMONARY HYPERTENSION
11.9 IMMUNE DEFICIENCY
11.1 ANEMIA
11.11 HEMOPHILIA
11.12 PSORIASIS
11.13 CYSTIC FIBROSIS
11.14 ULCERATIVE COLITIS
11.15 CROHN’S DISEASE
11.16 JUVENILE IDIOPATHIC ARTHRITIS
11.17 GROWTH HORMONE DEFICIENCIES
11.18 HEPATITIS C VIRUS
11.19 OTHERS
12 CANADA SPECIALTY PHARMACY MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: CANADA
13 SWOT ANALYSIS
14 COMPANY PROFILES
14.1 BAYSHORE HEALTHCARE
14.1.1 COMPANY SNAPSHOT
14.1.2 PRODUCT PORTFOLIO
14.1.3 RECENT DEVELOPMENTS
14.2 MCKESSON CANADA
14.2.1 COMPANY SNAPSHOT
14.2.2 PRODUCT PORTFOLIO
14.2.3 RECENT DEVELOPMENTS
14.3 SOBEYS INC.
14.3.1 COMPANY SNAPSHOT
14.3.2 PRODUCT PORTFOLIO
14.3.3 RECENT DEVELOPMENTS
14.4 AURORA HEALTH CARE
14.4.1 COMPANY SNAPSHOT
14.4.2 PRODUCT PORTFOLIO
14.4.3 RECENT DEVELOPMENTS
14.5 REXALL PHARMACY GROUP ULC
14.5.1 COMPANY SNAPSHOT
14.5.2 PRODUCT PORTFOLIO
14.5.3 RECENT DEVELOPMENTS
14.6 ANDREEN'S PHARMACY
14.6.1 COMPANY SNAPSHOT
14.6.2 PRODUCT PORTFOLIO
14.6.3 RECENT DEVELOPMENTS
14.7 ALPINE DRUG MART I.D.A.
14.7.1 COMPANY SNAPSHOT
14.7.2 PRODUCT PORTFOLIO
14.7.3 RECENT DEVELOPMENTS
14.8 ALLCURES PHARMACY
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENTS
14.9 ABBY PHARMACY
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENTS
14.1 AARONSON'S COMPOUNDING PHARMACY
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENTS
14.11 BALANCED HEALTH INTEGRATIVE PHARMACY
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 1.11. 3 RECENT DEVELOPMENTS
14.12 BRUNSKILLPHARMACY
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENTS
14.13 BUDGET PHARMACY
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENTS
14.14 BIOSCRIPT SOLUTIONS
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENT
14.15 BAINS PHARMACY
14.15.1 COMPANY SNAPSHOT
14.15.2 PRODUCT PORTFOLIO
14.15.3 RECENT DEVELOPMENTS
14.16 360CARE DENMAN PHARMACY
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENTS
14.17 COMPOUNDING PHARMACY NEW WESTMINSTER- LONGEVITY PHARMACY
14.17.1 COMPANY SNAPSHOT
14.17.2 PRODUCT PORTFOLIO
14.17.3 RECENT DEVELOPMENTS
14.18 CITY LIFE PHARMACY & COMPOUNDING CENTRE
14.18.1 COMPANY SNAPSHOT
14.18.2 PRODUCT PORTFOLIO
14.18.3 RECENT DEVELOPMENTS
14.19 CREATE COMPOUNDING LTD.
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENTS
14.2 CONCORD SPECIALTY PHARMACY
14.20.1 COMPANY SNAPSHOT
14.20.2 PRODUCT PORTFOLIO
14.20.3 1.20.3RECENT DEVELOPMENTS
14.21 DYNASTY PHARMACY
14.21.1 COMPANY SNAPSHOT
14.21.2 PRODUCT PORTFOLIO
14.21.3 RECENT DEVELOPMENTS
14.22 EXTEND PHARMACY
14.22.1 COMPANY SNAPSHOT
14.22.2 PRODUCT PORTFOLIO
14.22.3 RECENT DEVELOPMENTS
14.23 LOVELL DRUGS
14.23.1 COMPANY SNAPSHOT
14.23.2 PRODUCT PORTFOLIO
14.23.3 RECENT DEVELOPMENTS
14.24 LONDON DRUGS
14.24.1 COMPANY SNAPSHOT
14.24.2 PRODUCT PORTFOLIO
14.24.3 RECENT DEVELOPMENT
14.25 MCCALLUM PHARMACY
14.25.1 COMPANY SNAPSHOT
14.25.2 PRODUCT PORTFOLIO
14.25.3 RECENT DEVELOPMENTS
14.26 MEDLANDIA.COM
14.26.1 COMPANY SNAPSHOT
14.26.2 PRODUCT PORTFOLIO
14.26.3 RECENT DEVELOPMENTS
14.27 MEDICINE CENTRE
14.27.1 COMPANY SNAPSHOT
14.27.2 PRODUCT PORTFOLIO
14.27.3 RECENT DEVELOPMENTS
14.28 MOUNTAIN HEALTH CO-OP
14.28.1 COMPANY SNAPSHOT
14.28.2 PRODUCT PORTFOLIO
14.28.3 RECENT DEVELOPMENTS
14.29 MEDS PHARMACY
14.29.1 COMPANY SNAPSHOT
14.29.2 PRODUCT PORTFOLIO
14.29.3 RECENT DEVELOPMENTS
14.3 NORTHMOUNT PHARMACY AND COMPOUNDING LAB
14.30.1 COMPANY SNAPSHOT
14.30.2 PRODUCT PORTFOLIO
14.30.3 RECENT DEVELOPMENTS
14.31 NKS HEALTH (A SUBSIDIARY OF GREEN SHIELD)
14.31.1 COMPANY SNAPSHOT
14.31.2 PRODUCT PORTFOLIO
14.31.3 RECENT DEVELOPMENTS
14.32 ON-PHARM UNITED
14.32.1 COMPANY SNAPSHOT
14.32.2 PRODUCT PORTFOLIO
14.32.3 RECENT DEVELOPMENTS
14.33 OMNICARE PHARMACY
14.33.1 COMPANY SNAPSHOT
14.33.2 PRODUCT PORTFOLIO
14.33.3 RECENT DEVELOPMENTS
14.34 OMNICELL INC. (2022)
14.34.1 COMPANY SNAPSHOT
14.34.2 REVENUE ANALYSIS
14.34.3 PRODUCT PORTFOLIO
14.34.4 RECENT DEVELOPMENT
14.35 PHARMACHOICEANCHOR COMPOUNDING PHARMACY
14.35.1 COMPANY SNAPSHOT
14.35.2 PRODUCT PORTFOLIO
14.35.3 RECENT DEVELOPMENTS
14.36 PHARMACHOICE
14.36.1 COMPANY SNAPSHOT
14.36.2 PRODUCT PORTFOLIO
14.36.3 RECENT DEVELOPMENTS
14.37 PRATT'S COMPOUNDING PHARMACY
14.37.1 COMPANY SNAPSHOT
14.37.2 PRODUCT PORTFOLIO
14.37.3 RECENT DEVELOPMENTS
14.38 PHARMASAVE
14.38.1 COMPANY SNAPSHOT
14.38.2 PRODUCT PORTFOLIO
14.38.3 RECENT DEVELOPMENTS
14.39 PACE PHARMACY
14.39.1 COMPANY SNAPSHOT
14.39.2 PRODUCT PORTFOLIO
14.39.3 RECENT DEVELOPMENTS
14.4 QUIICK MEDICINE
14.40.1 COMPANY SNAPSHOT
14.40.2 PRODUCT PORTFOLIO
14.40.3 RECENT DEVELOPMENTS
14.41 RESIDENT CARE PHARMACY
14.41.1 COMPANY SNAPSHOT
14.41.2 PRODUCT PORTFOLIO
14.41.3 RECENT DEVELOPMENTS
14.42 RIVERVIEWGUARDIAN.CA
14.42.1 COMPANY SNAPSHOT
14.42.2 PRODUCT PORTFOLIO
14.42.3 RECENT DEVELOPMENTS
14.43 RX CONNECT
14.43.1 COMPANY SNAPSHOT
14.43.2 PRODUCT PORTFOLIO
14.43.3 RECENT DEVELOPMENTS
14.44 SRX HEALTH
14.44.1 COMPANY SNAPSHOT
14.44.2 PRODUCT PORTFOLIO
14.44.3 RECENT DEVELOPMENTS
14.45 SENTREX HEALTH SOLUTIONS
14.45.1 COMPANY SNAPSHOT
14.45.2 PRODUCT PORTFOLIO
14.45.3 RECENT DEVELOPMENTS
14.46 SHOPPERS DRUG MART SPECIALTY HEALTH NETWORK INC.
14.46.1 COMPANY SNAPSHOT
14.46.2 PRODUCT PORTFOLIO
14.46.3 RECENT DEVELOPMENTS
14.47 SHERMAN SPECIALTY PHARMACY
14.47.1 COMPANY SNAPSHOT
14.47.2 PRODUCT PORTFOLIO
14.47.3 RECENT DEVELOPMENTS
14.48 TORANI AND HADDAD PHARMACY SPEC- PHARMA
14.48.1 COMPANY SNAPSHOT
14.48.2 PRODUCT PORTFOLIO
14.48.3 RECENT DEVELOPMENTS
14.49 TOTAL PHARMACY
14.49.1 COMPANY SNAPSHOT
14.49.2 PRODUCT PORTFOLIO
14.49.3 RECENT DEVELOPMENTS
14.5 VICTORIA COMPOUNDING PHARMACY
14.50.1 COMPANY SNAPSHOT
14.50.2 PRODUCT PORTFOLIO
14.50.3 RECENT DEVELOPMENTS
14.51 WEST END PHARMACY
14.51.1 COMPANY SNAPSHOT
14.51.2 PRODUCT PORTFOLIO
14.51.3 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
List of Table
TABLE 1 LIST OF SMALL ENTERPRISES
TABLE 2 DATA OF NUMBER OF ELDERLY POPULATION IN CANADA
TABLE 3 CANADA HEALTHCARE (2018-2009)
TABLE 4 CANADA SPECIALTY PHARMACY MARKET, BY SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 5 CANADA CLINICAL SERVICES IN SPECIALTY PHARMACY MARKET, BY SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 6 CANADA MEDICAL CONSULTATIONS IN SPECIALTY PHARMACY MARKET, BY SERVICE TYPE 2021-2030 (USD MILLION)
TABLE 7 CANADA RISK EVALUATION AND MITIGATION STRATEGY (REMS) IN SPECIALTY PHARMACY MARKET, BY SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 8 CANADA OPERATIONAL SERVICES IN CANADA SPECIALTY PHARMACY MARKET, BY SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 9 CANADA SUPPLY CHAIN MANAGEMENT IN SPECIALTY PHARMACY MARKET, BY SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 10 CANADA INSURANCE NAVIGATION IN SPECIALTY PHARMACY MARKET, BY SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 11 CANADA SPECIALTY PHARMACY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 12 CANADA LARGE PHARMACY BENEFIT MANAGER (PBM) IN SPECIALTY PHARMACY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 13 CANADA SPECIALTY PHARMACY MARKET, BY CONDITION, 2021-2030 (USD MILLION)
TABLE 14 PREVALENCE (%) OF DIAGNOSED OSTEOARTHRITIS BY SEX AND AGE GROUP, CANADA
TABLE 15 HEMOPHILIA PREVALENCE BY IN BOTH GENDER
TABLE 16 PREVALENCE (%) OF DIAGNOSED JUVENILE IDIOPATHIC ARTHRITIS BY SEX AND AGE GROUP, CANADA
List of Figure
FIGURE 1 CANADA SPECIALTY PHARMACY MARKET: SEGMENTATION
FIGURE 2 CANADA SPECIALTY PHARMACY MARKET: DATA TRIANGULATION
FIGURE 3 CANADA SPECIALTY PHARMACY MARKET: DROC ANALYSIS
FIGURE 4 CANADA SPECIALTY PHARMACY MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 CANADA SPECIALTY PHARMACY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 CANADA SPECIALTY PHARMACY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 CANADA SPECIALTY PHARMACY MARKET: DBMR MARKET POSITION GRID
FIGURE 8 CANADA SPECIALTY PHARMACY MARKET: DBMR VENDOR SHARE ANALYSIS
FIGURE 9 CANADA SPECIALTY PHARMACY MARKET: SEGMENTATION
FIGURE 10 AN INCREASE IN THE PREVALENCE OF CHRONIC AND RARE DISEASES IS EXPECTED TO BOOST THE CANADA SPECIALTY PHARMACY MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 11 CLINICAL SERVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE CANADA SPECIALTY PHARMACY MARKET IN 2023 & 2030
FIGURE 12 DISTRIBUTION AND DISPENSE OF SPECIALTY DRUGS UNDER THE PHARMACY BENEFIT
FIGURE 13 DISTRIBUTION AND DISPENSE OF SPECIALTY DRUGS UNDER THE MEDICAL BENEFIT
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE CANADA SPECIALTY PHARMACY MARKET
FIGURE 15 CANADA SPECIALTY PHARMACY MARKET: BY SERVICE TYPE, 2022
FIGURE 16 CANADA SPECIALTY PHARMACY MARKET: BY SERVICE TYPE, 2023-2030 (USD MILLION)
FIGURE 17 CANADA SPECIALTY PHARMACY MARKET: BY SERVICE TYPE, CAGR (2023-2030)
FIGURE 18 CANADA SPECIALTY PHARMACY MARKET: BY SERVICE TYPE, LIFELINE CURVE
FIGURE 19 CANADA SPECIALTY PHARMACY MARKET: BY TYPE, 2022
FIGURE 20 CANADA SPECIALTY PHARMACY MARKET: BY TYPE, 2023-2030 (USD MILLION)
FIGURE 21 CANADA SPECIALTY PHARMACY MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 22 CANADA SPECIALTY PHARMACY MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 CANADA SPECIALTY PHARMACY MARKET: BY CONDITION, 2022
FIGURE 24 CANADA SPECIALTY PHARMACY MARKET: BY CONDITION, 2023-2030 (USD MILLION)
FIGURE 25 CANADA SPECIALTY PHARMACY MARKET: BY CONDITION, CAGR (2023-2030)
FIGURE 26 CANADA SPECIALTY PHARMACY MARKET: BY CONDITION, LIFELINE CURVE
FIGURE 27 CANADA SPECIALTY PHARMACY MARKET: COMPANY SHARE 2022 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.